David Dai
Stock Analyst at UBS
(0.42)
# 3,959
Out of 4,732 analysts
18
Total ratings
18.75%
Success rate
-23.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $29.02 | -17.30% | 1 | Oct 24, 2024 | |
| NUVL Nuvalent | Initiates: Neutral | $100 | $75.84 | +31.86% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $110.05 | -20.04% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $3.43 | +483.09% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $19.14 | +82.86% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $39.45 | +82.51% | 1 | Oct 24, 2024 | |
| KURA Kura Oncology | Initiates: Buy | $27 | $7.26 | +271.90% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $40.72 | +69.45% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $22.18 | +125.43% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $5.91 | +187.65% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $10.26 | +192.40% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $29.08 | +106.33% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $13.08 | +182.87% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.91 | +2,982.34% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $13.49 | +196.52% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.00 | +1,233.33% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.47 | +1,924.29% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $39.00 | +33.33% | 1 | Mar 17, 2020 |
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $29.02
Upside: -17.30%
Nuvalent
Oct 24, 2024
Initiates: Neutral
Price Target: $100
Current: $75.84
Upside: +31.86%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $110.05
Upside: -20.04%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.43
Upside: +483.09%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $19.14
Upside: +82.86%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $39.45
Upside: +82.51%
Kura Oncology
Oct 24, 2024
Initiates: Buy
Price Target: $27
Current: $7.26
Upside: +271.90%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $40.72
Upside: +69.45%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $22.18
Upside: +125.43%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $5.91
Upside: +187.65%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $10.26
Upside: +192.40%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $29.08
Upside: +106.33%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $13.08
Upside: +182.87%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.91
Upside: +2,982.34%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $13.49
Upside: +196.52%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.00
Upside: +1,233.33%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.47
Upside: +1,924.29%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $39.00
Upside: +33.33%